NeuroPace, Inc.
NeuroPace, Inc. (NPCE) Financial Performance & Income Statement Overview
Explore the financials of NeuroPace, Inc. (NPCE), including yearly and quarterly data on income, cash flow, and balance sheets.
NeuroPace, Inc. (NPCE) Income Statement & Financial Overview
View the income breakdown for NeuroPace, Inc. NPCE across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $21.47M | $21.06M | $19.26M | $18.12M |
| Cost of Revenue | $5.28M | $5.64M | $5.12M | $4.78M |
| Gross Profit | $16.19M | $15.42M | $14.13M | $13.34M |
| Gross Profit Ratio | $0.75 | $0.73 | $0.73 | $0.74 |
| R&D Expenses | $6.05M | $5.75M | $6.07M | $5.78M |
| SG&A Expenses | $13.79M | $13.91M | $14.30M | $15.10M |
| Operating Expenses | $19.84M | $19.66M | $20.36M | $20.89M |
| Total Costs & Expenses | $25.12M | $25.30M | $25.49M | $25.67M |
| Interest Income | $681000.00 | $754000.00 | $762000.00 | $827000.00 |
| Interest Expense | $2.19M | $2.18M | $2.17M | $2.26M |
| Depreciation & Amortization | $3.09M | $451000.00 | $444000.00 | $423000.00 |
| EBITDA | -$2.61M | -$2.82M | -$4.90M | -$6.24M |
| EBITDA Ratio | -$0.12 | -$0.13 | -$0.25 | -$0.34 |
| Operating Income | -$3.65M | -$4.24M | -$6.23M | -$7.54M |
| Operating Income Ratio | -$0.17 | -$0.20 | -$0.32 | -$0.42 |
| Other Income/Expenses (Net) | -$1.60M | -$1.21M | -$1.28M | -$1.38M |
| Income Before Tax | -$5.25M | -$5.45M | -$7.51M | -$8.93M |
| Income Before Tax Ratio | -$0.24 | -$0.26 | -$0.39 | -$0.49 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $379724.00 |
| Net Income | -$5.25M | -$5.45M | -$7.51M | -$8.93M |
| Net Income Ratio | -$0.24 | -$0.26 | -$0.39 | -$0.49 |
| EPS | -$0.18 | -$0.19 | -$0.26 | -$0.32 |
| Diluted EPS | -$0.18 | -$0.19 | -$0.26 | -$0.32 |
| Weighted Avg Shares Outstanding | $29.91M | $29.44M | $28.85M | $28.29M |
| Weighted Avg Shares Outstanding (Diluted) | $29.91M | $29.44M | $28.85M | $28.29M |
The company's financials show resilient growth, with revenue advancing from $18.12M in Q1 2024 to $21.47M in Q4 2024. Gross profit remained healthy with margins at 75% in Q4 2024 compared to 74% in Q1 2024. Operating income hit -$3.65M last quarter, sustaining a consistent -17% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$2.61M. Net income rose to -$5.25M, while earnings per share reached -$0.18. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan